Try our beta test site
39 studies found for:    (CLL [CONDITION]) AND PCI-32765 [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
Study Type: Interventional
Phase: Phase 3
Sponsor: German CLL Study Group
2 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Study Type: Interventional
Phase: Phase 1
Sponsor/Collaborators: Dana-Farber Cancer Institute;   Genentech, Inc.
3 Recruiting Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Study Type: Observational
Phase:
Sponsor: Oncology Institute of Southern Switzerland
4 Recruiting A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Study Type: Interventional
Phase:
Sponsor: M.D. Anderson Cancer Center
5 Recruiting A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: National Heart, Lung, and Blood Institute (NHLBI);   National Institutes of Health Clinical Center (CC)
6 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Study Type: Interventional
Phase: Phase 1
Sponsor/Collaborators: Michael Choi;   Pharmacyclics LLC.;   University of California, San Diego
7 Recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Study Type: Interventional
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: University of California, San Diego;   Pharmacyclics LLC.
8 Recruiting Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Study Type: Interventional
Phase: Phase 3
Sponsor/Collaborators: German CLL Study Group;   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Nordic CLL Study Group (NCLLSG);   Swiss Group for Clinical Cancer Research
9 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Study Type: Interventional
Phase: Phase 1
Sponsor: Aptevo Therapeutics
10 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Bristol-Myers Squibb
11 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Study Type: Interventional
Phase: Phase 1
Sponsor/Collaborators: Dana-Farber Cancer Institute;   TG Therapeutics, Inc.;   The Leukemia and Lymphoma Society
12 Recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   AbbVie
13 Recruiting Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
Study Type: Observational
Phase:
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
14 Not yet recruiting A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Study Type: Interventional
Phases: Phase 1 / Phase 2
Sponsor: University of California, San Diego
15 Recruiting Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Study Type: Interventional
Phase: Phase 3
Sponsor: Acerta Pharma BV
16 Recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: Farrukh Awan;   Pharmacyclics LLC.;   Ohio State University Comprehensive Cancer Center
17 Recruiting A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Study Type: Interventional
Phase: Phase 2
Sponsor: Acerta Pharma BV
18 Recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Study Type: Interventional
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Jeffrey Jones;   Ohio State University Comprehensive Cancer Center
19 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Genentech, Inc.;   Pharmacyclics LLC.
20 Recruiting Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Genentech, Inc.

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.